PDCD1 and cancer: Like other myeloid inhibitory Siglecs (such as Siglec-7 and -9), Siglec-3 has a downstream signaling function similar to other ITIM-containing immune checkpoint receptors like PD-1 and CTLA-4 [52,53], which are popular checkpoint targets for cancer treatment [49].